HOME >> MEDICINE >> NEWS
Low tar cigarettes do not cut lung cancer risk

The risk of lung cancer is no different in people who smoke medium tar cigarettes, low tar cigarettes, or very low tar cigarettes, concludes new research from the United States.

Researchers analysed the relation between the tar rating of the brand of cigarette smoked in 1982 and death from lung cancer over six years among 364,239 men and 576,535 women aged 30 years or more.

Irrespective of the tar level of their current brand, all current smokers had a far greater risk of lung cancer than people who had never smoked or who had quit.

Men and women who smoked very low tar (7 mg or less) and low tar (8-14 mg) brands had risks of lung cancer indistinguishable from those who smoked medium tar (15-21 mg) brands. This pattern did not change after demographic factors, dietary habits, and occupational and medical histories were taken into account.

Men and women who smoked non-filtered cigarettes with tar ratings of 22 mg or more had even higher risks of lung cancer.

These findings are consistent with other evidence that people smoke low tar cigarettes more intensively, and challenge the assumption that the link between tar rating and lung cancer risk is necessarily linear, say the authors.

They suggest that reducing the use of high tar non-filter cigarettes may provide limited public health benefits in those countries where these products are commonly used.


'"/>

Contact: Linda Millington
pressoffice@bma.org.uk
44-0-20-7383-6473
BMJ-British Medical Journal
8-Jan-2004


Page: 1

Related medicine news :

1. Tobacco-company-sponsored parties with free cigarettes may encourage students to start smoking
2. Majority of cigarettes in the US smoked by nicotine-dependent or psychiatrically ill persons
3. Activism prompts teen smokers to cut back on cigarettes, Stanford study finds
4. Heavy smokers see cigarettes as friends
5. UNC study shows Internet offers youths easy way to buy cigarettes
6. Rising cost of cigarettes may help smokers honor new years resolution to quit
7. Carcinogen in cigarettes causes mutation linked to lung cancer
8. Brain chemicals can thwart desire to smoke cigarettes
9. It is easy for adolescents to purchase cigarettes illegally in North Carolina
10. Hormonal treatment improves survival in high-risk prostate cancer patients
11. International breast cancer prevention study launches in the United States and Canada

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Low tar cigarettes not cut lung cancer risk

(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: